|
Published by: Global Markets Direct
Published: Dec. 8, 2010 - 84 Pages
Table of Contents- National Institute of Arthritis and Musculoskeletal and Skin Diseases Snapshot
- National Institute of Arthritis and Musculoskeletal and Skin Diseases Overview
- Key Information
- Key Facts
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Research and Development Overview
- Key Therapeutic Areas
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Combination Treatment Modalities
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Products Glance
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Late Stage Pipeline
- Phase III Products/Combination Treatment Modalities
- National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Drug Profiles
- Alendronate + Harmone Replacement Therapy
- Product Description
- Mechanism of Action
- R&D Progress
- Atorvastatin
- Product Description
- Mechanism of Action
- R&D Progress
- Azithromycin + Rifampin
- Product Description
- Mechanism of Action
- R&D Progress
- Cyclophosphamide
- Product Description
- Mechanism of Action
- R&D Progress
- Doxycycline + Rifampin
- Product Description
- Mechanism of Action
- R&D Progress
- Etanercept for Wegener's Granulomatosis
- Product Description
- Mechanism of Action
- R&D Progress
- Nitroglycerin Ointment
- Product Description
- Mechanism of Action
- R&D Progress
- Parathyroid hormone + Alendronate
- Product Description
- Mechanism of Action
- R&D Progress
- Paricalcitol
- Product Description
- Mechanism of Action
- R&D Progress
- Prednisone
- Product Description
- Mechanism of Action
- R&D Progress
- Prednisone + Methotrexate
- Product Description
- Mechanism of Action
- R&D Progress
- Prednisone + Etanercept
- Product Description
- Mechanism of Action
- R&D Progress
- PTH + Alendronate
- Product Description
- Mechanism of Action
- R&D Progress
- Rocaltrol
- Product Description
- Mechanism of Action
- R&D Progress
- Abatacept
- Product Description
- Mechanism of Action
- R&D Progress
- Acitretin
- Product Description
- Mechanism of Action
- R&D Progress
- BG9588
- Product Description
- Mechanism of Action
- R&D Progress
- Bovine Type II Collagen
- Product Description
- Mechanism of Action
- R&D Progress
- Cyclosporine
- Product Description
- Mechanism of Action
- R&D Progress
- Enbrel
- Product Description
- Mechanism of Action
- R&D Progress
- Fludarabine
- Product Description
- Mechanism of Action
- R&D Progress
- h5G1.1-mAb
- Product Description
- Mechanism of Action
- R&D Progress
- hPTH-(1-34)
- Product Description
- Mechanism of Action
- R&D Progress
- hPTH-(1-34) + Alendronate
- Product Description
- Mechanism of Action
- R&D Progress
- Ketoconazole
- Product Description
- Mechanism of Action
- R&D Progress
- Kineret
- Product Description
- Mechanism of Action
- R&D Progress
- Methimazole
- Product Description
- Mechanism of Action
- R&D Progress
- Methotrexate
- Product Description
- Mechanism of Action
- R&D Progress
- Methotrexate + Fludarabine
- Product Description
- Mechanism of Action
- R&D Progress
- Pamidronate
- Product Description
- Mechanism of Action
- R&D Progress
- Remicade_
- Product Description
- Mechanism of Action
- R&D Progress
- Rilonacept
- Product Description
- Mechanism of Action
- R&D Progress
- Rituximab
- Product Description
- Mechanism of Action
- R&D Progress
- StrataGraft Skin Tissue
- Product Description
- Mechanism of Action
- R&D Progress
- Teriparatide + Alendronate
- Product Description
- Mechanism of Action
- R&D Progress
- Testosterone + Somatropin
- Product Description
- Mechanism of Action
- R&D Progress
- Tripterygium wilfordi Hook F
- Product Description
- Mechanism of Action
- R&D Progress
- Cytoxan + Fludarabine
- Product Description
- Mechanism of Action
- R&D Progress
- Epratuzumab
- Product Description
- Mechanism of Action
- R&D Progress
- MRA 003 US
- Product Description
- Mechanism of Action
- R&D Progress
- SQ Fludarabine
- Product Description
- Mechanism of Action
- R&D Progress
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Analysis
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Products by Therapeutic Class
- National Institute of Arthritis and Musculoskeletal and Skin Diseases Pipeline Products By Target
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Products by Route of Administration
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline Products by Molecule Type
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Recent Pipeline Updates
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Dormant Projects
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Locations And Subsidiaries
- Head Office
- Recent Developments
- Jun 16, 2011: Stratatech Receives Fund From Defense Department For Phase IIb Trial For StrataGraft
- Feb 03, 2009: Stratatech Engineers Skin Substitute With Potent Anti-Infective Function
- Feb 03, 2009: Stratatech Engineers Skin Substitute With Potent Anti-Infective Function
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline by Therapy Area and Indication, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline by Stage of Development, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Monotherapy Products in Pipeline, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Combination Treatment Modalities in Pipeline, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Phase III, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Phase II, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Phase I, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Therapeutic Class, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Target, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Route of Administration, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Molecule Type, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Recent Pipeline Updates, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Dormant Developmental Projects, 2010
- List of Figures
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline by Therapy Area and Indication, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline by Stage of Development, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Monotherapy Products in Pipeline, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Combination Treatment Modalities in Pipeline, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Therapeutic Class, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Target, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Route of Administration, 2010
- National Institute of Arthritis and Musculoskeletal and Skin Diseases - Pipeline By Molecule Type, 2010
AbstractNational Institute of Arthritis and Musculoskeletal and Skin Diseases - Developmental Therapeutics Review - Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “National Institute of Arthritis and Musculoskeletal and Skin Diseases - Developmental Therapeutics Review - Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope - Review of therapeutics under development by National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Institute of Arthritis and Musculoskeletal and Skin Diseases with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of National Institute of Arthritis and Musculoskeletal and Skin Diseases’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy - Identify new drug targets and therapeutic classes in National Institute of Arthritis and Musculoskeletal and Skin Diseases’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate National Institute of Arthritis and Musculoskeletal and Skin Diseases’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of National Institute of Arthritis and Musculoskeletal and Skin Diseases in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- Avoid Intellectual Property Rights related issues.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
